Silverback Therapeutics Inc (SBTX) News

Current Report Filing (8-k)

false 0001671858 0001671858 2023-06-27 2023-06-27     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549  ...

Quarterly Report (10-q)

--12-310001671858falseQ10001671858spry:EquityIncentivePlansMemberspry:EquityIncentivePlan2018Member2023-03-310001671858us-gaap:AccumulatedOtherCo...

Current Report Filing (8-k)

false000167185800016718582023-05-152023-05-15  UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT...

Current Report Filing (8-k)

false 0001671858 0001671858 2023-05-09 2023-05-09   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549    ...

Report of Proposed Sale of Securities (144)

Form 144 Filer Information UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF...

Annual Report to Security Holders (ars)

Proxy Statement (definitive) (def 14a)

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549...

Annual Report (10-k)

FYfalse00016718580001671858spry:LicenseAgreementMemberspry:RecordatiAgreementMember2020-09-012020-09-300001671...

Current Report Filing (8-k)

0001671858false00016718582023-03-232023-03-23   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549...

Current Report Filing (8-k)

false 0001671858 0001671858 2023-03-13 2023-03-13     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549  ...

ARS Pharmaceuticals Announces Presentation of Data Supporting neffy (epinephrine nasal spray) and Real-World Burden of Needle Injectors

Data to be Presented in Five Poster Presentations at the 2023 American Academy of Allergy, Asthma and Immunology Annual Meeting Data Support New...

Current Report Filing (8-k)

false 0001671858 0001671858 2023-02-22 2023-02-22     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549  ...

ARS Pharmaceuticals Reacquires European Marketing Rights to neffy® (ARS-1) for the Treatment of Type I Allergic Reactions Including Anaphylaxis

SAN DIEGO, Feb. 22, 2023 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering...

Amended Statement of Ownership (sc 13g/a)

  UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Schedule 13G/A (Rule 13d-102) Amendment...

ARS Pharmaceuticals to Participate in the SVB Securities Virtual Global Biopharma Conference 2023

SAN DIEGO, Feb. 09, 2023 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering...